Molecular determinants of resistance to antiandrogen therapy
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Using microarray-based profiling of isogenic prostate cancer xenograft models, we found that a modest increase in androgen receptor mRNA was the only change consistently associated with the development of resistance to antiandrogen therapy. This increase in androgen receptor mRNA and protein was both necessary and sufficient to convert prostate cancer growth from a hormone-sensitive to a hormone-refractory stage, and was dependent on a functional ligand-binding domain. Androgen receptor antagonists showed agonistic activity in cells with increased androgen receptor levels; this antagonist-agonist conversion was associated with alterations in the recruitment of coactivators and corepressors to the promoters of androgen receptor target genes. Increased levels of androgen receptor confer resistance to antiandrogens by amplifying signal output from low levels of residual ligand, and by altering the normal response to antagonists. These findings provide insight toward the design of new antiandrogens.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FKBP51 overexpression was not detected in a previous microarray analysis of the LAPC-4 xenografts (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“which is known to promote AI-type growth in human prostate cancer models (3)”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“AR overexpression is a signature of AI disease, and forcing AR expression in model systems is sufficient to generate AI growth and responsiveness to antiandrogens (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“AR overexpression is a signature of AI disease, and forcing AR expression in model systems is sufficient to generate AI growth and responsiveness to antiandrogens (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“Several studies have provided evidence that this disease progression may be due in part to intratumoral synthesis of androgens, with castration-resistant prostate-cancer cells overexpressing the enzymes required for androgen biosynthesis.”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [35]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261 · cited 1×
“Because xenograft-specific expression signatures are likely to obscure the gene expression changes responsible for the transition from hormone-sensitive to hormone-refractory state”
BackgroundShiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729 · cited 1×
“Because steroid receptor–antagonist complexes adopt a variety of conformation”
BackgroundThe development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326 · cited 1×
“The postulated mechanisms to explain resistance to hormone therapy can be separated into three general categorie”
BackgroundThe coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233
Self-citationActivation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964 · cited 1×
“The kinases and substrates responsible for androgen receptor activation in this setting are unknown, but it is presumed to occur through downstream phosphorylation of androgen receptor–associated proteins or through the androgen receptor itself, analogous to the estrogen recepto”
BackgroundLNCaP model of human prostatic carcinoma.
Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H. E., Chu, T. M., MIRAND, E. A., & Murphy, G. P. (1983) · PubMed · Cited by 1,789
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
Molecular Determinants for the Tissue Specificity of SERMs
Shang, Y., & Brown, M. (2002) · Science · doi:10.1126/science.1068537 · Cited by 1,146 · cited 1×
“Previous work has shown that the agonist-versus-antagonist response of nuclear receptors, such as the estrogen receptor, is altered by increased expression of coactivators (such as SRC-1) or by decreased expression of corepressors (such as NCoR”
BackgroundNongenotropic, Sex-Nonspecific Signaling through the Estrogen or Androgen Receptors
Kousteni, S., Bellido, T., Plotkin, L. I., O'Brien, C. A., Bodenner, D. L., Han, L., Han, K., DiGregorio, G. B., Katzenellenbogen, J. A., Katzenellenbogen, B. S., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00268-9 · Cited by 1,113
Cited by
Items 201–300 of 1,002
Wang, H., Li, N., Liu, Q., Guo, J., Pan, Q., Cheng, B., Xu, J., Dong, B., Yang, G., Yang, B., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.05.016 · Cited by 171
Targeting the Androgen Signaling Axis in Prostate Cancer
Dai, C. S., Dehm, S. M., & Sharifi, N. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00433 · Cited by 194
Targeting androgen receptor phase separation to overcome antiandrogen resistance
Xie, J., He, H., Kong, W., Li, Z., Gao, Z., Xie, D., Sun, L., Fan, X., Jiang, X., Zheng, Q., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01151-y · Cited by 166
Nyquist, M. D., Li, Y., Hwang, T. H., Manlove, L. S., Vessella, R. L., Silverstein, K. A. T., Voytas, D. F., & Dehm, S. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308587110 · Cited by 171
Self-citationJiao, J., Wang, S., Qiao, R., Vivanco, I., Watson, P. A., Sawyers, C. L., & Wu, H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4202 · Cited by 172
“for cell-cycle progression in androgen-independent CWR22 (42) and LAPC4 (43), the specific role of AR in PTEN-controlled HRPC progression has not been clearly defined yet.”
BackgroundSelf-citationConverting Cancer Therapies into Cures: Lessons from Infectious Diseases
Glickman, M. S., & Sawyers, C. L. (2012) · Cell · doi:10.1016/j.cell.2012.02.015 · Cited by 168
Self-citationShi, X.-B., Xue, L., Ma, A.-H., Tepper, C. G., Gandour-Edwards, R., Kung, H.-J., & deVere White, R. W. (2013) · Oncogene · doi:10.1038/onc.2012.425 · Cited by 168
Attard, G., Reid, A. H. M., Olmos, D., & de Bono, J. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4531 · Cited by 168
“cancers may generate intracrine androgenic steroids or become ‘‘hypersensitive’’ to low steroid levels through AR gene mutations or amplification supporting continued tumor growth (1, 2).”
BackgroundLin, P.-C., Chiu, Y.-L., Banerjee, S., Park, K., Mosquera, J. M., Giannopoulou, E., Alves, P., Tewari, A. K., Gerstein, M. B., Beltran, H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2968 · Cited by 168
“Perhaps the most important recent finding came when Chen and colleagues discovered that androgen receptor signaling persists under stringent ADT and that androgen receptor antagonists act as agonists at high androgen receptor levels (5).”
Agoulnik, I. U., Vaid, A., Nakka, M., Alvarado, M., Bingman, W. E., Erdem, H., Frolov, A., Smith, C. L., Ayala, G. E., Ittmann, M. M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1023 · Cited by 168
“Increased AR expression in androgen-independent tumors relative to androgen-dependent tumors is consistently observed both in xenograft models (3) and in human tumors (4).”
Ottman, R., Nguyen, C., Lorch, R., & Chakrabarti, R. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-1 · Cited by 162
“It is now accepted that CRPC maintains functional AR signaling [10,11] but androgen refractoriness is through an AR bypass or adaptive mechanism, which is possibly, mediated through cytokines or other survival factors.”
BackgroundAndrogen regulation of micro‐RNAs in prostate cancer
Waltering, K. K., Porkka, K. P., Jalava, S. E., Urbanucci, A., Kohonen, P. J., Latonen, L. M., Kallioniemi, O. P., Jenster, G., & Visakorpi, T. (2011) · The Prostate · doi:10.1002/pros.21276 · Cited by 166
“The overexpression of AR seems to be sufficient to transform the androgen dependent growth of cancer cells to an androgen independent one both in vitro and in vivo [2,4].”
BackgroundAn update on androgen deprivation therapy for prostate cancer
Sharifi, N., Gulley, J. L., & Dahut, W. L. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-10-0187 · Cited by 165
“Bilateral orchiectomy, however, is significantly less expensive than medical castration (Chon et al. 2000).”
Zhang, Z., Zhou, C., Li, X., Barnes, S. D., Deng, S., Hoover, E., Chen, C.-C., Lee, Y. S., Zhang, Y., Wang, C., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.001 · Cited by 166
Self-citationKhan, N., Asim, M., Afaq, F., Abu Zaid, M., & Mukhtar, H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0240 · Cited by 163
“fact that PCa cells generally become androgen independent, they still depend on functional AR signaling, which is often overexpressed in hormone-refractory PCa, for growth (23), and decreasing AR levels impair their growth (24).”
BackgroundJohnson, A. B., & O’Malley, B. W. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.04.021 · Cited by 164
“In cells overexpressing AR, but not those lacking ARoverexpression, bicalutamide treatment resulted in the increased recruitment of SRC-1 and decreased recruitment of NCoR to the promoter of AR target genes, PSA and KLK-2 (Chen et al., 2004).”
BackgroundSong, B., Park, S.-H., Zhao, J. C., Fong, K.-W., Li, S., Lee, Y., Yang, Y. A., Sridhar, S., Lu, X., Abdulkadir, S. A., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122367 · Cited by 158
“A diverse array of molecular determinants have been reported in the past years, accounting for resistance to ADT, and out of which the most critical is aberrant activation of androgen receptor (AR) through various mechanisms, including alterations in cofactor activity (6, 7).”
BackgroundSelf-citationMechanisms of the development of androgen independence in prostate cancer
So, A., Gleave, M., Hurtado-Col, A., & Nelson, C. (2005) · World Journal of Urology · doi:10.1007/s00345-004-0473-1 · Cited by 162
“Similarly, Sawyers group recently showed that in their xenograft prostate cancer models, ‘‘hormone refractory’’ tumors remained dependent on ligand-binding to the AR [13].”
BackgroundZhang, L., Yang, S., Chen, X., Stauffer, S., Yu, F., Lele, S. M., Fu, K., Datta, K., Palermo, N., Chen, Y., et al. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00102-15 · Cited by 161
“Androgen receptor 405 overexpression, activation and androgen secretion are the major contributors to 406 androgen receptor-dependent CRPC (64-66).”
Androgen-Induced Coactivator ANCCA Mediates Specific Androgen Receptor Signaling in Prostate Cancer
Zou, J. X., Guo, L., Revenko, A. S., Tepper, C. G., Gemo, A. T., Kung, H.-J., & Chen, H.-W. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3440 · Cited by 160
“The primary functional mode of AR, a member of the nuclear hormone receptor superfamily, is believed to regulate gene transcription (5).”
BackgroundAsangani, I. A., Wilder-Romans, K., Dommeti, V. L., Krishnamurthy, P. M., Apel, I. J., Escara-Wilke, J., Plymate, S. R., Navone, N. M., Wang, S., Feng, F. Y., et al. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0472 · Cited by 158
Xin, L., Teitell, M. A., Lawson, D. A., Kwon, A., Mellinghoff, I. K., & Witte, O. N. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602567103 · Cited by 158
Role of Androgens on MCF-7 Breast Cancer Cell Growth and on the Inhibitory Effect of Letrozole
Macedo, L. F., Guo, Z., Tilghman, S. L., Sabnis, G. J., Qiu, Y., & Brodie, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3984 · Cited by 158
“The oligonucleotides encoding AR siRNA were 5¶-TGCACTGCTACTCTTCAGCATTCAAGAGATGCTGAAGAGTAGCAGTGCTTTTTTC-3¶ and 5¶-TCGAGAAAAAAGCACTGCTACTCTTCAGCATCTCTTGAATGCTGAAGAGTAGCAGTGCA-3¶ (32).”
BackgroundMicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer
Rokhlin, O. W., Scheinker, V. S., Taghiyev, A. F., Bumcrot, D., Glover, R. A., & Cohen, M. B. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.8.6284 · Cited by 159
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
Bakht, M. K., & Beltran, H. (2025) · Nature Reviews Urology · doi:10.1038/s41585-024-00900-z · Cited by 158
“The therapeutic landscape of castration-resistant prostate cancer (CRPC) has changed substantially over the past decade, in part precipitated by an increased understanding of the pivotal role of the androgen receptor (AR) signalling cascade in CRPC progression 1–4 .”
Hong, M. Y., Seeram, N. P., & Heber, D. (2008) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2007.11.006 · Cited by 168
“Since an elevated level of androgen causes enhancement of prostate cancer, reduction of circulating levels of androgens is central to the treatment of prostate cancer [22,23].”
BackgroundDeng, S., Wang, C., Wang, Y., Xu, Y., Li, X., Johnson, N. A., Mukherji, A., Lo, U.-G., Xu, L., Gonzalez, J., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00431-9 · Cited by 160
Saleem, M., Adhami, V. M., Zhong, W., Longley, B. J., Lin, C.-Y., Dickson, R. B., Reagan-Shaw, S., Jarrard, D. F., & Mukhtar, H. (2006) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0737 · Cited by 158
“The choice of these cells was based on the fact that 80% of patients with CaP present with androgen-dependent disease at the time of diagnosis, which later transforms into more aggressive, androgen-independent disease (27).”
BackgroundCellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications
Testa, U., Castelli, G., & Pelosi, E. (2019) · Medicines · doi:10.3390/medicines6030082 · Cited by 194
“A diverse array of molecular determinants has been reported accounting for resistance of prostate cancer cells to ADT and, among them, a key role is played by alterations in cofactor activity [162,445,643].”
BackgroundWatson, P. A., Ellwood-Yen, K., King, J. C., Wongvipat, J., LeBeau, M. M., & Sawyers, C. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-3441 · Cited by 159
“www.aacrjournals.org 11571 Cancer Res 2005; 65: ( 24 ).”
BackgroundInfluentialSelf-citationNi, L., Yang, C.-S., Gioeli, D., Frierson, H., Toft, D. O., & Paschal, B. M. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01891-08 · Cited by 155
“FKBP51 overexpression was not detected in a previous microarray analysis of the LAPC-4 xenografts (3).”
BackgroundMethodInfluentialWelti, J. C., Sharp, A., Yuan, W., Dolling, D. I., Rodrigues, D. N., Figueiredo, I., Gil, V., Neeb, A., Clarke, M., Seed, G., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3571 · Cited by 157
“The androgen receptor (AR) remains the main oncogenic driver for PC development and progression (2-5).”
BackgroundSecondary Hormonal Therapy for Advanced Prostate Cancer
Lam, J. S., Leppert, J. T., Vemulapalli, S. N., Shvarts, O., & Belldegrun, A. S. (2006) · Journal of Urology · doi:10.1016/s0022-5347(05)00034-0 · Cited by 153
Jin, L., Garcia, J., Chan, E., de la Cruz, C., Segal, E., Merchant, M., Kharbanda, S., Raisner, R., Haverty, P. M., Modrusan, Z., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0314 · Cited by 153
“In particular, we noted significant repression of AR target genes in 22RV1 cells, which remain insensitive to enzalutamide due to expression of ARDLBD.”
BackgroundInfluentialHaelens, A., Tanner, T., Denayer, S., Callewaert, L., & Claessens, F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1701 · Cited by 153
“The AR plays a key role in the development of prostate cancer and in resistance to hormone therapy (2, 3).”
BackgroundMechanisms of Therapeutic Resistance in Prostate Cancer
Nakazawa, M., Paller, C., & Kyprianou, N. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0568-7 · Cited by 154
Alterations of androgen receptor in prostate cancer
Linja, M. J., & Visakorpi, T. (2004) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2004.10.012 · Cited by 177
Deer antler – A novel model for studying organ regeneration in mammals
Li, C., Zhao, H., Liu, Z., & McMahon, C. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.07.007 · Cited by 155
“The transition from androgen-dependent to androgenindependent growth also occurs in prostate glands, another organ in males that is associated with secondary sexual characteristics, when a gland becomes cancerous (Chen et al., 2004).”
BackgroundMisawa, A., Takayama, K., Urano, T., & Inoue, S. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.718536 · Cited by 159
“Past studies have revealed that elevated AR expression (4), activation of AR transcription (11), and development of AR variants (12) are observed in the progression to CRPC, suggesting the importance of identifying AR downstream signals and new molecular mechanisms for AR activation to improve the treatment of CRPC.”
BackgroundWare, K. E., García-Blanco, M. A., Armstrong, A. J., & Dehm, S. M. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0470 · Cited by 166
“…on ADT does not typically occur through the mechanisms of bypassing androgen or AR dependence, as evidenced by studies demonstrating the importance of autocrine androgen synthesis and AR protein overexpression for castration-resistant PCa (CRPC; Chen et al. 2004, Stanbrough et al. 2006).”
Cai, C., Wang, H., Xu, Y., Chen, S., & Balk, S. P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0395 · Cited by 151
“models have shown that AR mRNA is highly expressed and increased compared with levels before androgen deprivation (7, 8, 18, 19).”
BackgroundThe vitamin D receptor in cancer: Symposium on ‘Diet and cancer’
Thorne, J. L., & Campbell, M. J. (2008) · Proceedings of The Nutrition Society · doi:10.1017/s0029665108006964 · Cited by 169
“PPAR((53,54)), and suggests a hitherto unsuspected flexibility of the VDR to associate with a diverse array of protein factors to adapt function((55,56)).”
BackgroundInfluentialSecond generation androgen receptor antagonists and challenges in prostate cancer treatment
Chen, Y., Zhou, Q., Hankey, W., Fang, X., & Yuan, F. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05084-1 · Cited by 170
“These results are consistent with earlier findings from Sawyer’s lab that GR upregulation contributes to enzalutamide and apalutamide resistance in LNCaP and VCaP cell models [12, 108].”
ResultSchalken, J. A., & Fitzpatrick, J. M. (2015) · British Journal of Urology · doi:10.1111/bju.13123 · Cited by 168
Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity
Cyrta, J., Augspach, A., Filippo, M. R. D., Prandi, D., Thienger, P., Benelli, M., Cooley, V., Bareja, R., Wilkes, D. C., Chae, S.-S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19328-1 · Cited by 158
ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers
Mahajan, K. N., & Mahajan, N. P. (2014) · Oncogene · doi:10.1038/onc.2014.350 · Cited by 154
Crosstalk between the Androgen Receptor and β-Catenin in Castrate-Resistant Prostate Cancer
Wang, G., Wang, J., & Sadar, M. D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1718 · Cited by 168
“Consistent with our results shown here, expressions of both AR and h-catenin have been reported to be elevated in castrate-resistant prostate cancer (46, 47).”
ResultSmall Molecule Inhibitors Targeting the “Achilles' Heel” of Androgen Receptor Activity
Sadar, M. D. (2011) · Cancer Research · doi:10.1158/0008-5472.can_10-3398 · Cited by 171
“org Cancer Res; 71(4) February 15, 2011 1211”
BackgroundInfluentialShibata, N., Nagai, K., Morita, Y., Ujikawa, O., Ohoka, N., Hattori, T., Koyama, R., Sano, O., Imaeda, Y., Nara, H., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00168 · Cited by 142
Yang, H., & Dou, Q. P. (2010) · Current Drug Targets · doi:10.2174/138945010791170842 · Cited by 160
“As a result, these hormoneindependent cancer cells are very sensitive to low or no androgen environments, and are responsive to a broad range of ligands such as growth factors, other steroid hormones, antiandrogens, etc [12, 13].”
BackgroundAndrogen Receptor on the Move: Boarding the Microtubule Expressway to the Nucleus
Thadani-Mulero, M., Nanus, D. M., & Giannakakou, P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0783 · Cited by 147
“Prompted by the established clinical activity of taxanes in CRPC, together with the fact that AR continues to drive disease progression despite prior antiandrogen therapies (35), we set out to investigate the role of tubulin and the impact of microtubule-targeting drugs on AR trafficking and signaling.”
Majumder, S., Liu, Y., Ford, O. H., Mohler, J. L., & Whang, Y. E. (2006) · The Prostate · doi:10.1002/pros.20438 · Cited by 148
Lang, S., Frame, F. M., & Collins, A. T. (2008) · The Journal of Pathology · doi:10.1002/path.2478 · Cited by 181
Wright, J. L., Kwon, E. M., Ostrander, E. A., Montgomery, R. B., Lin, D. W., Vessella, R., Stanford, J. L., & Mostaghel, E. A. (2011) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-1023 · Cited by 144
“Cancer Epidemiol Biomarkers Prev; 20(4) April 2011 Cancer Epidemiology, Biomarkers & Prevention 622”
BackgroundInfluentialSelf-citationThe evolving biology and treatment of prostate cancer
Taichman, R. S., Loberg, R. D., Mehra, R., & Pienta, K. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31791 · Cited by 146
The changing therapeutic landscape of castration-resistant prostate cancer
Yap, T. A., Zivi, A., Omlin, A. G., & Bono, J. S. D. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.117 · Cited by 159
“Available AR antagonists have agonistic properties in advanced-stage CRPC, either by increased sensitivity and activity caused by AR mutation, or through AR overexpression”
BackgroundNelson, P. S. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.1300 · Cited by 153
Seaton, A., Scullin, P., Maxwell, P. J., Wilson, C., Pettigrew, J., Gallagher, R., O'Sullivan, J. M., Johnston, P. G., & Waugh, D. J. J. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn109 · Cited by 143
Targeting the stromal androgen receptor in primary prostate tumors at earlier stages
Niu, Y., Altuwaijri, S., Yeh, S., Lai, K., Yu, S., Chuang, K., Huang, S., Lardy, H. A., & Chang, C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804701105 · Cited by 153
“gen/AR functions in both stromal and epithelial cells, which may be the reason why tumors of prostate cancer patients were suppressed at the beginning of treatment and then have a recurrence after ADT treatment (30).”
BackgroundUrbanucci, A., Sahu, B., Seppälä, J., Larjo, A., Latonen, L., Waltering, K. K., Tammela, T. L. J., Vessella, R. L., Lähdesmäki, H. J., Jänne, O. A., et al. (2011) · Oncogene · doi:10.1038/onc.2011.401 · Cited by 155
“, 2001), and it has been shown to sensitize cells to low levels of androgens (Kokontis et al., 1998; Chen et al., 2004; Waltering et al., 2009).”
BackgroundSelf-citationHodgson, M. C., Astapova, I., Cheng, S., Lee, L. J., Verhoeven, M. C., Choi, E., Balk, S. P., & Hollenberg, A. N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m408972200 · Cited by 144
Edwards, J., & Bartlett, J. M. S. (2005) · BJU International · doi:10.1111/j.1464-410x.2005.05526.x · Cited by 143
Gao, H., Ouyang, X., Banach-Petrosky, W. A., Gerald, W. L., Shen, M. M., & Abate-Shen, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606836103 · Cited by 141
Gerhardt, J., Montani, M., Wild, P. J., Beer, M., Huber, F., Hermanns, T., Müntener, M., & Kristiansen, G. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.10.021 · Cited by 148
The role of IL-6 in the radiation response of prostate cancer
Wu, C.-T., Chen, M.-F., Chen, W.-C., & Hsieh, C.-C. (2013) · Radiation Oncology · doi:10.1186/1748-717x-8-159 · Cited by 140
“; licensee BioMed Central Ltd Commons Attribution License (http://creativec reproduction in any medium, provided the or independent growth [1,2].”
BackgroundDeterminants of Receptor- and Tissue-Specific Actions in Androgen Signaling
Pihlajamaa, P., Sahu, B., & Jänne, O. A. (2015) · Endocrine Reviews · doi:10.1210/er.2015-1034 · Cited by 141
Androgen receptor action in hormone‐dependent and recurrent prostate cancer
Agoulnik, I. U., & Weigel, N. L. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20811 · Cited by 140
“Studies in human tumor xenografts comparing matched androgen-dependent and androgenindependent derivatives also show an increase in AR [Chen et al., 2004].”
BackgroundAndrogen Receptor Signaling in Prostate Cancer and Therapeutic Strategies
Jacob, A., Raj, R., Allison, D. B., & Myint, Z. W. (2021) · Cancers · doi:10.3390/cancers13215417 · Cited by 158
“In vitro models demonstrated conversion of bicalutamide to an AR agonist in presence of this aberration [42].”
BackgroundFrigo, D. E., Howe, M. K., Wittmann, B. M., Brunner, A. M., Cushman, I., Wang, Q., Brown, M., Means, A. R., & McDonnell, D. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2581 · Cited by 142
“Despite the unresponsiveness of the hormonerefractory disease to androgen-deprivation therapy, AR-regulated signaling pathways remain active and are necessary for cancer progression (3).”
Gregory, C. W., Whang, Y. E., McCall, W., Fei, X., Liu, Y., Ponguta, L. A., French, F. S., Wilson, E. M., & Earp, H. S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1158 · Cited by 142
Yamashita, S., Lai, K.-P., Chuang, K., Xu, D., Miyamoto, H., Tochigi, T., Pang, S., Li, L., Arai, Y., Kung, H.-J., et al. (2012) · Neoplasia · doi:10.1593/neo.111436 · Cited by 148
“The mechanisms underlying castration-resistant androgen receptor (AR)–mediated signaling remain unclear, although several possible mechanisms have been proposed [5–11].”
BackgroundMurata, T., Takayama, K., Katayama, S., Urano, T., Horie‐Inoue, K., Ikeda, K., Takahashi, S., Kawazu, C., Hasegawa, A., Ouchi, Y., et al. (2010) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2010.32 · Cited by 154
Rettig, M. B., Heber, D., An, J., Seeram, N. P., Rao, J. Y., Liu, H., Klatte, T., Belldegrun, A. S., Moro, A., Henning, S. M., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0136 · Cited by 142
Crona, D. J., & Whang, Y. E. (2017) · Cancers · doi:10.3390/cancers9060067 · Cited by 160
“AR amplification, leading to AR overexpression, enables progression to CRPC even in the setting of low circulating androgens due to ADT treatment [50].”
BackgroundOuyang, X., Jessen, W. J., Al‐Ahmadie, H. A., Serio, A. M., Lin, Y., Shih, W. J., Reuter, V. E., Scardino, P. T., Shen, M. M., Aronow, B. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6055 · Cited by 158
“These include the androgen receptor, whose up-regulated expression is of principal relevance for hormone refractory prostate cancer (19); Clusterin , an antiapoptotic gene that has been associated with poor prognosis (20); Ezh2 , a histone methyltransferase that is overexpressed during cancer progression and in hormon…”
BackgroundCholesterol accumulation in prostate cancer: A classic observation from a modern perspective
Krycer, J. R., & Brown, A. J. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.01.002 · Cited by 166
Pten Inactivation and the Emergence of Androgen-Independent Prostate Cancer
Shen, M. M., & Abate-Shen, C. T. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1271 · Cited by 162
“Moreover, the expression level of AR is frequently increased in androgenindependent prostate cancer (7), perhaps consistent with selection for adaptation to reduced androgen levels.”
BackgroundNuclear receptors: from molecular mechanisms to therapeutics
Frigo, D. E., Bondesson, M., & Williams, C. (2021) · Essays in Biochemistry · doi:10.1042/ebc20210020 · Cited by 164
Clinical relevance of androgen receptor alterations in prostate cancer
Jernberg, E., Bergh, A. R. J., & Wikström, P. (2017) · Endocrine Connections · doi:10.1530/ec-17-0118 · Cited by 156
“Increased AR expression is consistently seen in tumour epithelial cells during development of CRPC (2), whereas a loss of AR signalling is generally observed in the primary tumour and metastasis stroma (14).”
BackgroundHe, B., Bai, S., Hnat, A. T., Kalman, R. I., Minges, J. T., Patterson, C., & Wilson, E. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403117200 · Cited by 136
Hååg, P., Bektić, J., Bartsch, G. H., Klocker, H., & Eder, I. E. (2005) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2005.04.029 · Cited by 155
Androgen Receptor Cross-talk with Cell Signalling Pathways
Culig, Z. (2004) · Growth Factors · doi:10.1080/08977190412331279908 · Cited by 138
“Moreover, a microarray-based comparison between therapy-sensitive and therapy-resistant xenografts revealed that the most consistent change associated with tumour escape is an increase in AR expression (Chen et al., 2004).”
BackgroundHuang, W., Hennrick, K. T., & Drew, S. A. (2012) · Human Pathology · doi:10.1016/j.humpath.2012.05.009 · Cited by 137
Denmeade, S. R., Wang, H., Agarwal, N., Smith, D. C., Schweizer, M. T., Stein, M. N., Assikis, V. J., Twardowski, P. W., Flaig, T. W., Szmulewitz, R. Z., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02759 · Cited by 144
“Total number of metastases, median (range) 2 (1-10) 2 (1-8) Patients with visceral metastases, n (%) 52 (55.”
BackgroundAndrogen receptor (AR) heterogeneity in prostate cancer and therapy resistance
Jamroze, A., Chatta, G. S., & Tang, D. G. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.006 · Cited by 155
CDK9 Regulates AR Promoter Selectivity and Cell Growth through Serine 81 Phosphorylation
Gordon, V. L., Bhadel, S., Wunderlich, W., Zhang, J., Ficarro, S. B., Mollah, S., Shabanowitz, J., Hunt, D. F., Xénarios, I., Hahn, W. C., et al. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0238 · Cited by 152
“There is a precedent for the tight control of AR expression in biological systems; slight overexpression of the AR can increase cell and tumor growth, which is consistent with our observations with wild-type AR in LHS and LAPC4 cells (17).”
MethodResultInfluentialVasaitis, T., Belosay, A., Schayowitz, A., Khandelwal, A., Chopra, P., Gediya, L. K., Guo, Z., Fang, H.-B., Njar, V. C. O., & Brodie, A. M. H. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0230 · Cited by 135
“overexpression of AR in a castration-resistant xenograft model is consistent with observations in human clinical specimens, and overexpression of AR promotes the transition from a hormone-dependent xenograft to a castration-resistant xenograft (5, 47).”
BackgroundShiota, M., Yokomizo, A., Tada, Y., Inokuchi, J., Kashiwagi, E., Masubuchi, D., Eto, M., Uchiumi, T., & Naito, S. (2009) · Oncogene · doi:10.1038/onc.2009.322 · Cited by 139
“Several studies have shown that progression to CRPC could be associated with an increased level of AR expression, indicating that AR downregulation should suppress tumor growth, even in CRPC (Gregory et al., 1998; Zegarra-Moro et al., 2002; Chen et al., 2004; Scher and Sawyers, 2006).”
BackgroundCooperation between Polycomb and androgen receptor during oncogenic transformation
Zhao, J. C., Yu, J., Runkle, C., Wu, L., Hu, M., Wu, D., Liu, J. S., Wang, Q., Qin, Z. S., & Yu, J. (2011) · Genome Research · doi:10.1101/gr.131508.111 · Cited by 148
Adaptation or selection—mechanisms of castration-resistant prostate cancer
Zong, Y., & Goldstein, A. S. (2012) · Nature Reviews Urology · doi:10.1038/nrurol.2012.237 · Cited by 162
Sun, A., Tawfik, O., Gayed, B., Thrasher, J. B., Hoestje, S., Li, C., & Li, B. (2007) · The Prostate · doi:10.1002/pros.20521 · Cited by 134
Bai, S., He, B., & Wilson, E. M. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.4.1238-1257.2005 · Cited by 133
“The MAGE-11-induced stabilization of AR in the absence of hormone could account for the increased levels of AR frequently observed with recurrent prostate cancer (3, 28, 46) and may contribute to the increased ligand-independent AR transcriptional activity.”
BackgroundMolecular Pathogenesis and Progression of Prostate Cancer
Schrecengost, R. S., & Knudsen, K. E. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.04.001 · Cited by 159
Bonham, M. J., Posakony, J., Coleman, I. M., Montgomery, B., Simon, J. A., & Nelson, P. S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1974 · Cited by 132
Long non‐coding RNAs and prostate cancer
Misawa, A., Takayama, K., & Inoue, S. (2017) · Cancer Science · doi:10.1111/cas.13352 · Cited by 141
Schweizer, M. T., Haugk, K. L., McKiernan, J. S., Gulati, R., Cheng, H. H., Maes, J. L., Dumpit, R. F., Nelson, P. S., Montgomery, B., McCune, J. S., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198389 · Cited by 145
A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer
Westaby, D., de la Maza, M. D. F., Paschalis, A., Jiménez‐Vacas, J. M., Welti, J. C., Bono, J. S. D., & Sharp, A. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052220-015912 · Cited by 145
Androgen Receptor Antagonists in Castration-Resistant Prostate Cancer
Rathkopf, D., & Scher, H. I. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e318282635a · Cited by 129
“This trial demonstrated substantial anti-tumor activity for patients treated with MDV3100 both before and after chemotherapy, credentialing the cell-based screen used to identify the compound and other preclinical models.(13,14) There was evidence of activity based on PSA declines at all dose levels tested, with a pla…”
BackgroundMethodInfluentialRoy, S., Kaur, M., Agarwal, C., Tecklenburg, M., Sclafani, R. A., & Agarwal, R. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0104 · Cited by 138
“therapy and no suitable cure is available thus far for this advanced stage of malignancy (7).”
BackgroundMolecular and cellular mechanisms of castration resistant prostate cancer (Review)
Huang, Y., Jiang, X., Liang, X., & Jiang, G. (2018) · Oncology Letters · doi:10.3892/ol.2018.8123 · Cited by 192
“On the other hand, increased AR was an unique gene expression alteration that was sustained in different CRPC xenograft tumor samples (18).”
Background
Metadata
- Authors
- Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L.
- Affiliations
- University of California, Los Angeles (US)
- Howard Hughes Medical Institute (US)
- University of Washington (US)
- Corresponding author
- Sawyers, Charles L
- Venue
- Nature Medicine
- Published
- 2003-12-21
- Volume
- 10
- Issue
- 1
- Pages
- 33-39
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2003955264
- Cited by
- 2,278
- References
- 50
- Citations by year
- 2026: 21 · 2025: 40 · 2024: 40 · 2023: 72 · 2022: 59 · 2021: 86 · 2020: 68 · 2019: 82 · 2018: 99 · 2017: 110 · 2016: 106 · 2015: 119 · 2014: 128 · 2013: 156 · 2012: 155
- FWCI
- 69.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- prostate cancer, antiandrogen resistance, androgen receptor, castration-resistant prostate cancer, androgen receptor ligand-binding domain, coactivator recruitment, corepressor recruitment, androgen receptor target genes
- MeSH terms
- Androgen Antagonists, Base Sequence, Humans, Male, Prostatic Neoplasms, Receptors, Androgen, DNA Primers, Disease Progression, Antineoplastic Agents, Hormonal, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.